{"id":6172,"date":"2025-03-27T13:48:33","date_gmt":"2025-03-27T10:48:33","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=6172"},"modified":"2025-03-27T13:48:33","modified_gmt":"2025-03-27T10:48:33","slug":"key-tavr-highlights-at-acc-25","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/key-tavr-highlights-at-acc-25\/","title":{"rendered":"Key TAVR Highlights at ACC.25"},"content":{"rendered":"
Key TAVR Highlights at ACC.25<\/div>\n
Highlighted by AHA.<\/div>\n
<\/div>\n
1. Major TAVR Companies Presenting New Data<\/div>\n
\u2022 Medtronic and Edwards Lifesciences, the two leading TAVR companies, will showcase their latest research and innovations at ACC.25 (March 29\u201331, Chicago).<\/span><\/div>\n
\u2022 Medtronic\u2019s Evolut valves and Edwards\u2019 Sapien 3 valves remain the dominant TAVR platforms in the U.S.<\/span><\/div>\n
\u2022 New clinical data will be presented, focusing on long-term TAVR outcomes, early treatment for AS, and technological advancements.<\/span><\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n
2. Medtronic\u2019s Key Presentations<\/div>\n
\u2022 Evolut Low Risk Trial (Five-Year Data) \u2013 March 30, 10:30 a.m.<\/span><\/div>\n
\u2022 Long-term outcomes comparing TAVR (Evolut) to surgical aortic valve replacement (SAVR) in low-risk patients.<\/span><\/div>\n
\u2022 Previously, four-year results confirmed TAVR\u2019s safety, effectiveness, and cost efficiency.<\/span><\/div>\n
\u2022 The five-year results will be a major highlight, providing further evidence on TAVR\u2019s durability.<\/span><\/div>\n
\u2022 Medtronic emphasizes superior valve performance, better patient outcomes, and robust clinical evidence supporting its TAVR technology.<\/span><\/div>\n
<\/div>\n
<\/div>\n
3. Edwards Lifesciences\u2019 Key Presentations<\/div>\n
\u2022 EARLY TAVR Study (March 31, 11:00 a.m. & 1:48 p.m.)<\/span><\/div>\n
\u2022 Investigates the benefits of performing TAVR in asymptomatic severe AS patients instead of waiting for symptoms to appear.<\/span><\/div>\n
\u2022 Two presentations will explore:<\/span><\/div>\n
1. Early conversions to TAVR \u2013 Why some patients in the study had to undergo TAVR sooner than expected.<\/span><\/div>\n
2. Biomarker-based risk assessment \u2013 How biomarkers (e.g., BNP, troponin) predict AS progression and help identify high-risk patients.<\/span><\/div>\n
\u2022 Electronic Provider Notifications for AS Detection (March 30, 2:15 p.m.)<\/span><\/div>\n
\u2022 Evaluates automated alerts in electronic medical records to detect severe AS earlier.<\/span><\/div>\n
\u2022 Could improve early diagnosis, faster referrals, and better patient outcomes.<\/span><\/div>\n
<\/div>\n
<\/div>\n
4. \u2018The Future of TAVR\u2019 Session \u2013 March 30, 3:30 p.m.<\/div>\n
\u2022 A dedicated session discussing emerging trends in TAVR, including:<\/span><\/div>\n
\u2022 Expanding TAVR to moderate AS patients (PROGRESS & EXPAND TAVR II trials).<\/span><\/div>\n
\u2022 Potential to prevent cardiac fibrosis and heart failure in earlier-stage AS.<\/span><\/div>\n
\u2022 Long-term evolution of TAVR vs. SAVR in treatment strategies.<\/span><\/div>\n
\u2022 Experts will provide insights into how TAVR is reshaping valvular heart disease management.<\/span><\/div>\n
<\/div>\n
<\/div>\n
Conclusion<\/div>\n
<\/div>\n
ACC.25 will showcase critical TAVR advancements, particularly regarding early intervention, long-term durability, and AI-driven detection. Medtronic and Edwards Lifesciences continue to push innovation in valve performance, patient selection, and clinical outcomes, setting the stage for TAVR\u2019s expanding role in cardiology.<\/div>\n
<\/div>\n
For more information about ACC.25, including registration details and a full schedule. https:\/\/accscientificsession.acc.org\/<\/div>\n","protected":false},"excerpt":{"rendered":"

Key TAVR Highlights at ACC.25 Highlighted by AHA. 1. Major TAVR Companies Presenting New Data \u2022 Medtronic and Edwards Lifesciences, the two leading TAVR companies, will showcase their latest research and innovations at ACC.25 (March 29\u201331, Chicago). \u2022 Medtronic\u2019s Evolut valves and Edwards\u2019 Sapien 3 valves remain the dominant TAVR platforms in the U.S. \u2022 […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6172","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6172"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6172\/revisions"}],"predecessor-version":[{"id":6173,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6172\/revisions\/6173"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}